Connective tissue polypeptides in serum as parameters to monitor antifibrotic treatment in hepatic fibrogenesis
- 31 December 1991
- journal article
- review article
- Published by Elsevier in Journal of Hepatology
- Vol. 13, S17-S25
- https://doi.org/10.1016/0168-8278(91)90004-u
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Steroid treatment lowers hepatic fibroplasia, as explored by serum aminoterminal procollagen III peptide, in chronic liver diseaseLiver International, 2008
- Serum concentrations of the carboxyterminal cross-linking domain of procollagen type IV (NC1) and the aminoterminal propetide of procollagen type III (PIIIP) in chronic liver diseaseJournal of Hepatology, 1990
- Is measurement of type III procollagen amino propeptide useful in primary biliary cirrhosis?Journal of Hepatology, 1989
- TYPE III PROCOLLAGEN PEPTIDE: A MARKER OF DISEASE ACTIVITY AND PROGNOSIS IN PRIMARY BILIARY CIRRHOSISThe Lancet, 1988
- Serum basement membrane and type III procollagen-related antigens in primary biliary cirrhosisJournal of Hepatology, 1988
- Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronanLiver International, 1987
- Serum concentration of the aminoterminal procollagen type III peptide in the rat reflects early formation of connective tissue in experimental liver cirrhosisJournal of Hepatology, 1986
- Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitisJournal of Hepatology, 1986
- The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosisJournal of Hepatology, 1986
- Blood analysis for liver fibrosisJournal of Hepatology, 1985